Continued progress toward submitting Investigational Device Exemption (“IDE”), and if approved, the commencement of U.S. clinical trials to support a De Novo FDA application THE WOODLANDS, TX, Aug. 14 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback